HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.107.045864v1 49/1/22    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beer, A. J. Articles by Schwaiger, M. Search for Related Content PubMed PubMed Citation Articles by Beer, A. J. Articles by Schwaiger, M.

Comparison of Integrin _vβ₃ Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using ¹⁸F-Galacto-RGD and ¹⁸F-FDG

¹ Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; ² Department of Hematology and Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; and ³ Department of Radiology, Klinikum rechts der Isar, Technische Universität München

Correspondence: For correspondence or reprints contact: Ambros J. Beer, MD, Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany. E-mail: beer{at}roe.med.tum.de

The expression of _vβ₃ and glucose metabolism are upregulated in many malignant lesions, and both are known to correlate with an aggressive phenotype. We evaluated whether assessment of _vβ₃ expression and of glucose metabolism with PET using ¹⁸F-galacto-RGD and ¹⁸F-FDG provides complementary information in cancer patients. Methods: Eighteen patients with primary or metastatic cancer (non–small cell lung cancer [NSCLC], n = 10; renal cell carcinoma, n = 2; rectal cancer, n = 2; others, n = 4) were examined with PET using ¹⁸F-galacto-RGD and ¹⁸F-FDG. Standardized uptake values (SUVs) were derived by volume-of-interest analysis. ¹⁸F-Galacto-RGD and ¹⁸F-FDG PET results were compared using linear regression analysis for all lesions (n = 59; NSCLC, n = 39) and for primaries (n = 14) and metastases to bone (n = 11), liver (n = 10), and other organs (n = 24) separately. Results: The sensitivity of ¹⁸F-galacto-RGD PET compared with clinical staging was 76%. SUVs for ¹⁸F-FDG ranged from 1.3 to 23.2 (mean ± SD, 7.6 ± 4.9) and were significantly higher than SUVs for ¹⁸F-galacto-RGD (range, 0.3–6.8; mean ± SD, 2.7 ± 1.5; P < 0.001). There was no significant correlation between the SUVs for ¹⁸F-FDG and ¹⁸F-galacto-RGD for all lesions (r = 0.157; P = 0.235) or for primaries, osseous or soft-tissue metastases separately (P > 0.05). For the subgroup of lesions in NSCLC, there was a weak correlation between ¹⁸F-FDG and ¹⁸F-galacto-RGD uptake (r = 0.353; P = 0.028). Conclusion: Tracer uptake of ¹⁸F-galacto-RGD and ¹⁸F-FDG does not correlate closely in malignant lesions. Whereas ¹⁸F-FDG PET is more sensitive for tumor staging, ¹⁸F-galacto-RGD PET warrants further evaluation for planning and response evaluation of targeted molecular therapies with antiangiogenic or _vβ₃-targeted drugs.

Key Words: _vβ₃ • ¹⁸F-galacto-RGD • ¹⁸F-FDG • PET • oncology

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				A. R. Hsu and X. Chen Advances in Anatomic, Functional, and Molecular Imaging of Angiogenesis J. Nucl. Med., April 1, 2008; 49(4): 511 - 514. [Abstract] [Full Text] [PDF]

				K. J. Langen and S. M. Eschmann Correlative Imaging of Hypoxia and Angiogenesis in Oncology J. Nucl. Med., April 1, 2008; 49(4): 515 - 516. [Full Text] [PDF]